NEW YORK (GenomeWeb News) – Dutch biotech company Crucell said today that Toyobo Gene Analysis will evaluate Crucell’s cell line technology for use in producing recombinant proteins for third-party customers.
Toyobo Gene Analysis is a wholly-owned subsidiary of Osaka, Japan-based Toyobo.
Crucell’s Star Technology contains elements that “enable stable and high-yield gene expression important to recombinant antibody and protein production in mammalian cells,” the company said. Crucell believes this technology could be used to increase production yields of recombinant proteins, which could lower the cost of producing them.
Financial terms of the agreement were not released.